Global Search

Hide Filters

Showing 2776 results

Ad hoc release / Apr 25, 2023

Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose

Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz wuchs im ersten Quartal um +8% (kWk1, +3% USD), und das operative Kernergebnis verbesserte sich um +15% (kWk, +8% USD) Innovative…
Press release / Apr 26, 2023

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase…
Press release / Apr 26, 2023

Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of…
Press release / Apr 26, 2023

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase…
Press release / May 04, 2023

Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six…
Press release / May 09, 2023

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform…
Press release / May 11, 2023

Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III…
Press release / Mar 07, 2023

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire

Les actionnaires approuvent la 26e augmentation consécutive du dividende à CHF 3,20 (+3,2%) par action pour 2022 ; représentant un rendement de 4.0%1 et une distribution du free cash-flow d…
Press release / Mar 07, 2023

Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut

Die Aktionärinnen und Aktionäre genehmigen die 26. Dividendenerhöhung in Folge auf CHF 3,20 (+3,2 %) pro Aktie für 2022; dies entspricht einer Rendite von 4.0 %1 und einer Ausschüttung von…
Press release / Mar 09, 2023

Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines

Sandoz investment expected to be at least USD 400m – MOU signed today in Ljubljana at ceremony led by Slovenian Prime Minister and Sandoz CEO New project underpins Sandoz ambition to drive…